Market Cap
$2.2B
PBH
Prestige Consumer Healthcare Inc.
$45.26 ▲ +1.09%
Prev close $44.77Market cap$2.2B
12-mo target$67.80 (+49.8%)
High Impact Filing (7/10)32 New Institutional Positions18 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on PBH right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Inst. Holders
50 funds
Inst. Value
$2.2B
Inst. Activity
32 buys / 18 sells
Insider Activity
$0.00 buy / $186.4K sell
Insider Net $
-$186.4K
SEC Reports
4
Press Releases
1
Price chart 30d -13.9%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 8, 2026 routine
Prestige Consumer Healthcare Inc. to Participate in Barclays Global Consumer Conference
TARRYTOWN, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) tod
Aug 19, 2026 Event
Aug 6, 2026 SEC CLEAR EYES Maximum Itchy Eye Relief, 0.5 fl oz (15 mL) per dropper bottle, Sterile, Dist. by Medtech Products Inc., Tarrytown, NY 10591, a Prestige Consumer Healthcare Company. NDC: 67172-999-01 UPC 6 78112 65920 3
Class II: Lack of assurance of sterility. The recall is due to potential contamination
Prestige Consumer Healthcare reported Q1 FY2027 revenue of $265.7M (+6.5% YoY) and adjusted diluted EPS of $0.98 (+3.2%
PRESS-RELEASE — Impact 6/10
Aug 4, 2026 Insider
Clark Celeste A. was granted 2,981 shares
Director
Aug 4, 2026 Insider
ZIER DAWN M. was granted 2,981 shares
Director
Aug 4, 2026 Insider
Jul 6, 2026 Press Kelly John F. was granted 2,981 shares
Director
Prestige closed its $150M acquisition of LaCorium Health, priced a $400M 6.25% senior notes offering to refinance its 5.
Impact 5/10
Jun 30, 2026 Inst.
FULLER & THALER ASSET — NEW
2,331,821 shares ($110.2M)
Analyst ratings buy % -12.5%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| May 15, 2026 | Canaccord Genuity | MAINTAIN | Buy | 47% |
| May 14, 2026 | Oppenheimer | DOWNGRADE | Perform | 52% |
| May 7, 2026 | Oppenheimer | MAINTAIN | Outperform | 52% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 3 | 4 | 3 | 0 | 0 | 70% | |
| Aug 1, 2026 | 3 | 4 | 3 | 0 | 0 | 70% | |
| Jul 1, 2026 | 3 | 4 | 3 | 0 | 0 | 70% | |
| Jun 1, 2026 | 3 | 4 | 3 | 0 | 0 | 70% | |
| May 1, 2026 | 4 | 4 | 2 | 0 | 0 | 80% | |
| Apr 1, 2026 | 4 | 4 | 2 | 0 | 0 | 80% | |
| Mar 1, 2026 | 4 | 4 | 2 | 0 | 0 | 80% | |
| Feb 1, 2026 | 4 | 4 | 2 | 0 | 0 | 80% |
Price targets
Where 5 covering analysts think PBH trades over the next 12 months.
$67.80 +49.8% upside Strong Buy
Current$45.26 Low$55.00 Median$70.00 High$75.00 5 analysts
$55.00$75.00
Analyst rating Buy· 1.7/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
4 SEC filing reports analyzed · 1 bullish, 1 bearish, 1 mixed, 1 neutral · avg impact 5.3/10.Plus 1 press releases.
BULLISHPRESS-RELEASE6/10
Prestige Consumer Healthcare reported Q1 FY2027 revenue of $265.7M (+6.5% YoY) and adjusted diluted
Aug 6, 2026
MIXED8-K6/10
Prestige Consumer Healthcare completed its $1.045B acquisition of the Breathe Right brand from Found
Jun 16, 2026
BEARISH8-K7/10
Prestige Consumer Healthcare reported Q4 FY2026 revenue of $281.6M (down 5.0% YoY) and GAAP diluted
May 13, 2026
NEUTRAL1442/10
Officer Jeffrey Zerillo filed a Form 144 to sell 305 shares of Prestige Consumer Healthcare, valued
May 7, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 8, 2026
routine
Prestige Consumer Healthcare Inc. to Participate in Barclays Global Consumer Conference
TARRYTOWN, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that Ron Lombardi, Chairman, Presiden
Sep 2, 2026
ftd
FTD: PBH — 10,652 shares ($0.6M) failed to deliver
Settlement: 20260902, Price: $52.64, FTD Value: $560,721.28, PRESTIGE CONSUMER HEALTHCARE I
Aug 19, 2026
FDA
CLEAR EYES Maximum Itchy Eye Relief, 0.5 fl oz (15 mL) per dropper bottle, Sterile, Dist. by Medtech Products Inc., Tarrytown, NY 10591, a Prestige Consumer Healthcare Company. NDC: 67172-999-01 UPC 6 78112 65920 3
Class II: Lack of assurance of sterility. The recall is due to potential contamination
Aug 19, 2026
FDA
CLEAR EYES Maximum Itchy Eye Relief, 0.5 fl oz (15 mL) per dropper bottle, Sterile, Dist. by Medtech Products Inc., Tarrytown, NY 10591, a Prestige Consumer Healthcare Company. NDC: 67172-999-01 UPC 6 78112 65920 3
Class II: Lack of assurance of sterility. The recall is due to potential contamination
Aug 19, 2026
FDA
CLEAR EYES Maximum Itchy Eye Relief, 0.5 fl oz (15 mL) per dropper bottle, Sterile, Dist. by Medtech Products Inc., Tarrytown, NY 10591, a Prestige Consumer Healthcare Company. NDC: 67172-999-01 UPC 6 78112 65920 3
Class II: Lack of assurance of sterility. The recall is due to potential contamination
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $1.07 | $1.05–$1.08 | 24.3% | +0.0% | 0↑ 1↓ | $0.3B | 7 |
| Next Q | $1.24 | $1.20–$1.31 | 8.9% | +0.0% | 0↑ 2↓ | $0.4B | 7 |
| Current FY | $4.57 | $4.45–$4.63 | 4.3% | +0.0% | 1↑ 1↓ | $1.3B | 8 |
| Next FY | $5.08 | $4.72–$5.35 | 11.3% | +0.0% | 1↑ 0↓ | $1.4B | 8 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $1.069 | — |
| 7d ago | $1.069 | — |
| 30d ago | $1.069 | — |
| 60d ago | $1.147 | -0.078 |
| 90d ago | $1.100 | -0.031 |
Institutional ownership
Which big funds own PBH (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $2.2B total value (46,568,464 shares) as of 2026-Q2. Top holders: BlackRock,, ARIEL, VANGUARD. Net buying activity: 32 institutions added/increased vs 18 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 7,831,333 | $370.2M | 16.8% | — |
| ARIEL INVESTMENTS, LLC | 4,868,711 | $230.1M | 10.4% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2,825,340 | $133.6M | 6.1% | — |
| DIMENSIONAL FUND ADVISORS LP | 2,661,291 | $125.8M | 5.7% | — |
| FULLER & THALER ASSET MANAGEMENT, INC. | 2,331,821 | $110.2M | 5.0% | NEW |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,136,944 | $101.0M | 4.6% | — |
| STATE STREET CORP | 2,116,513 | $100.0M | 4.5% | — |
| BRANDES INVESTMENT PARTNERS, LP | 2,051,060 | $97.0M | 4.4% | DOUBLED +140.1% |
| KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC | 1,872,023 | $88.5M | 4.0% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 1,571,742 | $74.3M | 3.4% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| FULLER & THALER ASSET MANAGEMENT, INC. | NEW | — | 2,331,821 | — | $110.2M |
| BRANDES INVESTMENT PARTNERS, LP | DOUBLED | 854,119 | 2,051,060 | +140.1% | $97.0M |
| NORDEA INVESTMENT MANAGEMENT AB | ADD | 599,375 | 828,628 | +38.2% | $39.3M |
| WESTWOOD HOLDINGS GROUP INC | TRIM | 1,119,715 | 750,445 | -33.0% | $35.5M |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | ADD | 473,151 | 658,659 | +39.2% | $31.1M |
| UBS Group AG | ADD | 392,209 | 638,605 | +62.8% | $30.2M |
| GOLDMAN SACHS GROUP INC | ADD | 457,618 | 586,536 | +28.2% | $27.7M |
| CITADEL ADVISORS LLC | DOUBLED | 183,440 | 564,157 | +207.5% | $26.7M |
| Woodline Partners LP | ADD | 273,943 | 359,721 | +31.3% | $17.0M |
| VICTORY CAPITAL MANAGEMENT INC | DOUBLED | 20,063 | 232,998 | +1061.3% | $11.0M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
10 insiders, 38 transactions. Net -$186.4K — $0.00 bought, $186.4K sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 4, 2026 | Clark Celeste A. | Director | AWARD | 2,981 | — | — |
| Aug 4, 2026 | ZIER DAWN M. | Director | AWARD | 2,981 | — | — |
| Aug 4, 2026 | Kelly John F. | Director | AWARD | 2,981 | — | — |
| Aug 4, 2026 | DArecca James | Director | AWARD | 2,981 | — | — |
| Aug 4, 2026 | BYOM JOHN E | Director | AWARD | 2,981 | — | — |
| May 11, 2026 | Zerillo Jeffrey | Senior VP Operations | SELL | 351 | $52.28 | $18.4K |
| May 7, 2026 | Lombardi Ronald M. | Chief Executive Officer | TAX W/H | 2,543 | $54.59 | $138.8K |
| May 7, 2026 | Mekhail Adel | EVP, Marketing & Sales | TAX W/H | 487 | $54.59 | $26.6K |
| May 7, 2026 | Sacco Christine | CFO & COO | TAX W/H | 991 | $54.59 | $54.1K |
| May 7, 2026 | Zerillo Jeffrey | Senior VP Operations | TAX W/H | 351 | $54.59 | $19.2K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for PBH.
Shares short
4,794,058
Settlement Sep 15, 2026
Change vs prior
+4.6%
Semi-monthly cycle
Days to cover
9.4
At avg daily volume
Of shares outstanding
≈10.1%
Estimate — not % of float
All PBH filing & press-release reports (5)
- PRESS-RELEASE reportAug 6, 2026
- PRESS-RELEASE reportJul 6, 2026
- 8-K reportJun 16, 2026
- 8-K reportMay 13, 2026
- 144 reportMay 7, 2026